echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Phase III. Clinical studies of the New Coronary Vaccine III.Co., D.D., have resumed in Brazil

    Phase III. Clinical studies of the New Coronary Vaccine III.Co., D.D., have resumed in Brazil

    • Last Update: 2021-01-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On the morning of November 11, 2020, local time, Brazil's National Health Supervision Agency (Anvisa) announced the authorization to resume clinical studies of the new corona inactivated vaccine Kellefort™️ III, supported by the Butantan Institute, a partner of Coching Bio.
    an emergency suspension of clinical studies on the evening of November 9 after an earlier failure to receive a report from the Butantan Institute.
    10 November, the Butantan Institute communicated with Anvisa, and the report of the Data Security Monitoring Committee (DSMB) was submitted to Anvisa on the same day.
    decision to resume clinical studies was made in a very timely manner after evaluating the new data.
    and resumption of research is a common event in clinical studies, and suspension does not necessarily mean that the product being studied has quality, safety or effectiveness issues, said Anvisa.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.